omega-n-methylarginine has been researched along with candesartan in 5 studies
| Studies (omega-n-methylarginine) | Trials (omega-n-methylarginine) | Recent Studies (post-2010) (omega-n-methylarginine) | Studies (candesartan) | Trials (candesartan) | Recent Studies (post-2010) (candesartan) |
|---|---|---|---|---|---|
| 4,411 | 344 | 336 | 1,929 | 412 | 589 |
| Protein | Taxonomy | omega-n-methylarginine (IC50) | candesartan (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 3.2769 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 5.9472 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 3.0652 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 9 | |
| Adenosine receptor A3 | Homo sapiens (human) | 1.2199 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 3 | |
| Beta-3 adrenergic receptor | Homo sapiens (human) | 4.3 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 1.2199 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 3.843 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 3.0652 | |
| Thromboxane-A synthase | Homo sapiens (human) | 3.0594 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0405 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 1.2199 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akashi, K; Asayama, J; Kawahara, A; Keira, N; Kobara, M; Matoba, S; Nakagawa, M; Tatsumi, T | 1 |
| Ghiadoni, L; Magagna, A; Salvetti, A; Taddei, S; Virdis, A | 1 |
| Drexler, H; Hornig, B; Kohler, C; Schlink, D; Tatge, H | 1 |
| Fujita, N; Manabe, H; Matsumoto, N; Naito, Y; Ochiai, J; Oka, S; Takagi, T; Uemura, M; Yoshida, N; Yoshikawa, T | 1 |
| Buikema, H; de Zeeuw, D; Gschwend, S; Henning, RH; Pinto, YM; van Gilst, WH | 1 |
2 trial(s) available for omega-n-methylarginine and candesartan
| Article | Year |
|---|---|
Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension.
Topics: Acetylcholine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Female; Humans; Hypertension; Male; Middle Aged; Nitric Oxide; Norepinephrine; omega-N-Methylarginine; Peptides, Cyclic; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Vasoconstrictor Agents; Vasodilator Agents | 2000 |
AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2-receptor-dependent mechanism.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Flow Velocity; Bradykinin; Bradykinin Receptor Antagonists; Coronary Artery Disease; Endothelium, Vascular; Enzyme Inhibitors; Humans; Infusions, Intra-Arterial; Middle Aged; Nitric Oxide Synthase; Nitroprusside; omega-N-Methylarginine; Radial Artery; Receptor, Angiotensin, Type 1; Receptor, Bradykinin B2; Receptors, Bradykinin; Tetrazoles | 2003 |
3 other study(ies) available for omega-n-methylarginine and candesartan
| Article | Year |
|---|---|
Cardioprotective effect of angiotensin-converting enzyme inhibition against hypoxia/reoxygenation injury in cultured rat cardiac myocytes.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Bradykinin; Cell Hypoxia; Cells, Cultured; Cilazapril; Creatine Kinase; Cyclic GMP; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Guanidines; Indomethacin; Methylene Blue; Muscle Fibers, Skeletal; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide; Nitric Oxide Synthase; omega-N-Methylarginine; Oxygen; Rats; Rats, Wistar; Staurosporine; Tetrazoles | 1999 |
An AT1-receptor antagonist and an angiotensin-converting enzyme inhibitor protect against hypoxia-induced apoptosis in human aortic endothelial cells through upregulation of endothelial cell nitric oxide synthase activity.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aorta; Apoptosis; Benzimidazoles; Biphenyl Compounds; Bradykinin; Caspase 3; Caspases; Cell Hypoxia; Cells, Cultured; Endothelium, Vascular; Humans; Imidazoles; Necrosis; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; omega-N-Methylarginine; Pyridines; Tetrazoles; Thiazepines | 2003 |
Myogenic constriction is increased in mesenteric resistance arteries from rats with chronic heart failure: instantaneous counteraction by acute AT1 receptor blockade.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Captopril; Chronic Disease; Coronary Vessels; Disease Models, Animal; Endothelium-Dependent Relaxing Factors; Endothelium, Vascular; Fatty Acids, Unsaturated; Heart; Heart Failure; Hydrazines; Imidazoles; Indomethacin; Lisinopril; Losartan; Male; Mesenteric Arteries; Nitric Oxide; omega-N-Methylarginine; Pyridines; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Superoxide Dismutase; Sympathetic Nervous System; Tetrazoles; Tetrodotoxin; Vascular Resistance | 2003 |